Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued
Wells Fargo upgraded RxSight Inc. (NASDAQ:RXST) from Equal Weight to Overweight on Monday, while raising its price target from $17 to $25 due to an attractive valuation at the current stock price.